Key Findings
The United States pharmaceutical continuous manufacturing market is expected to register a CAGR of 10.45%, over the forecast period. The country’s market growth is mainly fueled by the advantages of the free pricing policy, the presence of well-established players, and the initiatives introduced by government agencies. The base year considered for the studied market is 2020, and the forecast years are from 2021 to 2026.

Market Insights
The United States’ free pricing policy is a significant advantage to the nation’s pharmaceutical continuous manufacturing market. On account of the COVID-19 pandemic, in 2020, the United States is projected to shift its main manufacturing units from China, to other regions of Southeast Asia. As a result, the move would decrease the country’s reliance on the Chinese market for most of the pharmaceutical products. This strategy is expected to fuel the United States’ market growth, over the upcoming years.
As per the Pharmaceutical Research and Manufacturers Association (PhRMA), the United States-based organizations orchestrate more than half the global R&D activities for pharmaceuticals. Moreover, they also hold intellectual property rights on several new medicines. Conversely, the United States Food and Drug Administration (FDA) is considered one of the chief regulatory bodies, worldwide. Its product approvals are also swift, with a median period of nearly 13 months. However, the approval process’ drawback includes the recently defined pathway for biosimilars, permitting interchangeability. Thus, such factors are set to influence the country’s market growth, during the forecast period.

Competitive Insights
Some of the key companies operating in the market are, Eli Lilly and Company, Munson Machinery Company, Pfizer Inc, etc.
Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments